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Summary.-A case-control study was conducted in Los Angeles County, California,
of 163 very young breast-cancer cases (all aged 32 or less at diagnosis) to investigate
the role, if any, of oral contraceptives (OC) in the development of the disease. OC
use before first full-term pregnancy (FFTP) was associated with an elevated risk,
which increased with duration of OC use (relative risk 2-2 at 6 years of use, P <0.01).
This increased risk could not be explained by other risk factors. OC use after FFTP
was not associated with any change in risk. A first-trimester abortion before FFTP,
whether spontaneous or induced, was associated with a 2*4-fold increase in breast-
cancer risk (P <0-005).
PREVIOUS CASE-CONTROL STUDIES have
shown no evidence or, at most, little
evidence of an increased risk of breast
cancer in users of oral contraceptives
(Arthes et al., 1971; fHenderson et al., 1974;
Fasal & Paffenbarger, 1975: Paffenbarger
et al., 1977; Sartwell et al., 1977; Kelsey et
al., 1978; Lees et al., 1978; Brinton et al.,
1979; Paffenbarger et al., 1979; Vessey et
al., 1979). However, large-scale use of
these compounds did not begin until the
mid-1960s, and it is possible that these
studies did not find much evidence of an
association because long-term use of oral
contraceptives was still uincommon, and
there may be a long latent period between
first exposure and disease. Furthermore,
breast-cancer risk rises dramatically with
age, so that, even if studies are restricted
to premenopausal women, most cases will
be in their 40s. These previous studies have
thus, in fact, measured risk associated
with oral contraceptive use in the middle
and later years ofreproductive life, mostly
after the first full-term pregnancy.
Age at first full-term pregnancy is, how-
ever, a critical risk factor for breast cancer
(MacMahon et al., 1973) and we have
interpreted this to mean that the adoles-
cent and early adult years before first full-
term pregnancy are a critical period for
establishing breast-cancer risk. If this is
so, oral contraception during this period
could substantially alter the subsequent
risk of breast cancer. For a case-control
study to have a reasonable chance of
including women who used oral contra-
ceptives for a prolonged period early in
life it is essential to restrict the age of
diagnosis of the breast-cancer cases to
young women.
WXe report here the results of our
case-control study of 163 breast-cancer
patients who were aged under 33 at
dliagnosis.
METHOS)$
The patients wvere white womeni with
microscopically confirmed breast cancer first
diagnosed between July 1972 and December
1978. Any such woman, unless she had a
Spanish surname and wNas born outside the
United States. was eligible for inclusion if she
wNas uinder 33 years of age and a resident of
Los Angeles County at the date of her diag-
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nosis. The patients were identified by the
University of Southern California Cancer
Surveillance Program (CSP), the population-
based cancer registry for Los Angeles County
(Mack, 1977).
The CSP identified 293 eligible cases. As
the questionnaire requested details on repro-
ductive history and contraceptive use we
decided to restrict the study to living patients.
This reduced the eligible number to 245. The
hospital or attending physician granted us
permission to contact 212 (87%) of these
living patients, of whom we were unable to
locate 21. Among the 191 patients contacted
about the study, 24 refused to be inter-
viewed, so that we obtained completed
questionnaires on 167 (87%). Four of these
patients were excluded because of other
malignancies before their diagnosis of breast
cancer, leaving uswith a studyof163 patients.
We sought 2 individually matched con-
trols for each of the 163 study patients. The
first control was a neighbourhood control,
the second a friend control. These controls
had to be malignancy-free, white (excluding
foreign-born if they had a Spanish surname)
and with birth dates within 5 years of their
matched case. They also had to be at least as
old at interview as their matched case was at
diagnosis.
For the neighbourhood control we used a
procedure that defines a sequence of houses
on specified neighbourhood blocks. Our goal
was to interview the first matching female
resident in the sequence. If no one was home
at the time of visit, we left an explanatory
letter and made a follow-up visit after
several days. In 138 instances, the first
appropriate person agreed to cooperate.
When, in 16 other instances, the first match
refused to participate, the next matched con-
trol in the sequence was located. For any
patient, 40 housing units were visited and 3
return visits made before failure to secure a
matched control was conceded. In all, 153
matched neighbourhood controls were found
and questionnaires completed.
Each patient was also requested to provide
the name of a school friend with whom she
had maintained contact; to avoid bias we
used a selection algorithm which began with
high-school friends. Friend controls were
found and interviewed for 119 cases. We
obtained one or both controls for all cases.
All interviews were conducted by telephone
by I.R. Information thus obtained included
reproductive, menstrual, contraceptive, and
gynaecological history, hormone and other
drug use, and family history of cancer, up to
the date of diagnosis of breast cancer. Each
control was given a "pseudodiagnosis" date
which was the date on which she would have
been the exact age her matched patient was
at diagnosis of breast cancer. The diagnosis/
pseudodiagnosis date is referred to below as
the "relevant date". The use of any drugs for
the first time within 6 months ofthe relevant
date was ignored.
Multivariate logistic regression methods
for individually matched case-control studies
were used for statistical analysis (Breslow et
at., 1978; Holford et al., 1978; Pike et al.,
1980).
RESULTS
No significant differences were found
between our analyses using either only the
neighbourhood controls or only the friend
controls, so we have considered both con-
trols simultaneously in the analysis pre-
sented here. 65% of the controls had
birth dates within 2 years oftheir matched
control, and on average they were born 9
months earlier.
The relative risk (RR) for breast cancer
was statistically significantly increased by
a history ofthe disease in mother or sister
(1st-degree relative), by a history of
benign breast disease, by earlier menarche,
and by long-term use of oral contra-
ceptives (Table I). RR was decreased by
having had a full-term (28 weeks or longer)
pregnancy, but the result was not statistic-
ally significant, and there was no clear
trend with the age at first full-term preg-
nancy (FFTP).
RR for oral contraceptive (OC) use was
roughly doubled if we only considered use
before FFTP (Table II). RR was 3'5 for
8 or more years' use before FFTP, and the
trend of increasing RR with increasing
duration of use was statistically highly
significant (1-sided P < 0O01). No type of
OC could be identified as particularly
associated with this increased risk, nor
could any type be clearly exonerated. OC
use after FFTP was not statistically sig-
nificantly related to the risk of breast
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TABLE I.-Relative risks (RR) for various possible breast-cancer riskfactors
Factor
History ofbreast cancer in mother or sister:
History ofbenign breast disease:
Age at menarche:
Ever had a full-term pregnancy (FFTP):
Age at FFTP:
Use oforal contraceptives (OC):
Yes
No
Yes
No
Under 12
12
13+
Yes
No
Never
Under 20
20-24
25+
Never
1-48 mo.
49+ mo.
Cases
20
143
32
131
49
52
62
109
54
54
39
44
26
28
75
60
Controls
7
263
27
243
61
67
142
189
81
81
66
89
34
52
141
77
RR*
5-63
2-11
1-00
090
0*50
0*77
1-00
0-81
0*67
1-01
1-00
1-08
1-56
Pt
0-001
0-004
0 004+
0-16
0-0211
* Matched relative risk.
t 1-sided statistical significance level.
t For linear trend to actual age at menarche.
§ For trend in age at FFTP based only on parous women.
11 For linear trend to actual number of months used.
TABLE II.-Risk of breast cancer in relation to use of oral contraceptives (OC) before and
afterfirstfull-termpregnancy (FFTP)
Factor
OC before FFTP
OC after FFTPt
Duration
(months) Cases Controls
0 79 141
1-48 53 103
49-96 24 22
97+ 7 4
0
1-48
49-96
97+
20
38
15
5
40
53
24
7
RR
1-00
1-02
2-25
3-52
1-00
1-56
1-31
1-74
* For linear trend to actual number of months used.
t Parous women only.
53ancer, and there was no trend with dura-
tion of use. The increased relative risk
associated with OC before FFTP was
hardly altered by adjusting for family
history of breast cancer, age at menarche
and whether or not the woman had had a
FFTP.
There was however a clear (and statistic-
ally significant) interaction between the
RRs associated with a history of benign
breast disease (BBD) and with OC before
FFTP (OCB). OC carried a substantially
greater RR in women with BBD. Table III
shows our data categorized by OCB and
BBD diagnosed before FFTP (BBDB).
When we consider the 4 controls and 11
cases with BBDB who used OC we find:
(i) 2 cases developed BBD before starting
OC, (ii) BBD developed after stopping OC
in all 4 controls and in 6 cases, and (iii) 3
cases developed BBD while taking O0 (all
after at least 48 months' continuous OC).
For this paper we have considered a
woman as having BBD if she said she had
been treated for BBD and the disease was
not clearly simply associated with fullness
of the breast at a specific time in the
menstrual cycle. We are currently under-
taking a detailed review ofboth the clinical
details and histology of the BBD in these
cases and controls.
RR of breast cancer was also clearly
p
0.009*
0.30*
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TABLE III.-Risk of breast
tion to OC before FFTP an
disease (BBD) diagnosed b
oc
duration
BBD (months)
No 0
1-48
49+
Yes 0
1-48
49+
Cases
73
49
24
6
4
7
C
* Unmatched RR relative to r:
FFTP and no history of BBD.
TABLE IV.-Riskofbreast ca
to early abortion* befo?
Abortion
before
FFTP
Yes
No
Cases Controls
24 17
139 253
* Duration of pregnancy < 12 w
increased in women hai
trimester abortion before
(RR=2-4, 1-sided P<O000
It did not matter whether
was spontaneous or induce
abortions in cases were indi
in controls. RR was howe
reduced (RR= 1.8) in wom
quently had a FFTP. TI
factors discussed above a
pendent of the risk associa
early abortion. Pregnancies
than 3 months that ended i]
not carry any increased r
cancer; nor did abortions aj
DISCUSSION
The present case-control
Angeles area white women
years of age provides clear
long-term use of oral contrai
the first full-term pregnancn
substantially increased risk
cer. This increased risk was
by association with other I
cancer risk factors. The
whether this increased ris
cancer in rela- older-aged patients is very important, and
4d benign breast warrants continued study.
before FFTP The 2 case-control studies of Paffen-
barger and his colleagues (1977, 1979) also
found an increased risk of breast cancer
'ontrols RR* associated with OC before "first child-
134 1-00 birth" (RR=2-7 and 1.24). They were,
26 0969 however, studying an older group of
7 1-57 breast-cancer patients, and their results
4 1-84 were based on very few cases: in the first
0 °° study there were 17 cases and no data
io OC use before were given on duration of OC; in the
second study there were 16 cases, only 4
of whom had used OC for more than 2
rncerinrelation years. Paffenbarger et al. (1979) also re-
re FFTP ported an increased risk (RR= 1-8) among
nulliparous women who used OC for more
than 4 years, but the result was again not RR P statistically significant. Other published
2*40 O-OO4 studies have few relevant observations.
Vessey et al. (1979) found that breast-
eeks. cancer patients who had used the pill
during the year before diagnosis had a
ving a first- better prognosis than other breast-cancer
their FFTP patients. As we only studied living
15, Table IV). patients, such an effect could erroneously
the abortion suggest that OC was associated with
,d: 11/24 such breast-cancer risk. We investigated this
aced, and 8/17 possible bias by dividing the cases into
ver somewhat strata depending on the length of time
en who subse- from diagnosis to interview, but found no
he other risk evidence that this influenced the OC
ppeared inde- finding.
,ted with such Multivariate analysis of our data sug-
3 lasting more gests that the risk factors of mother or
n abortion did sister with breast cancer, and early
risk of breast menarche, both act in such a way that
fter the FFTP. the joint risk associated with these con-
ditions and OC is the product of the risks
associated with each. This implies that the
added risk of such OC use by these high
study of Los risk women is more than for other women.
less than 33 The results of OC use and benign breast
evidence that disease (BBD) (see Table III) are a little
ceptives before difficult to interpret, since OC is known to
y may carry a decrease the frequency of BBD, so that
of breast can- BBD in a woman who has used OC is not
not explained strictly comparable to the disease in a
known breast- woman who has not. Nevertheless, con-
question of sideration of when the BBD was diag-
k extends to nosed allows one to draw a number of
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conclusions. Firstly, the development of
BBD while actually using OC or after
prolonged use of OC carries with it a very
high risk of subsequent breast cancer.
Secondly, OC needs to be used with
caution in all women with a history of
BBD. The amount ofdata we have on this
latter point is very small, but it agrees
with the studies of Lees et al. (1978) and
Brinton et al. (1979) both ofwhich suggest
that OC at any time in women with BBD
may increase the risk of breast cancer.
The results of the two studies of Paffen-
barger and his colleagues (1977, 1979)
contradict one another on this point.
Our finding that a first-trimester abor-
tion, whether spontaneous or induced,
before first full-term pregnancy appears to
cause a substantial increase in risk of
subsequent breast cancer has not to our
knowledge been reported before. Mac-
Mahon and his colleagues in their inter-
national case-control studies did find
abortion to be associated with a slight
increase in breast-cancer risk, but they
did not specifically study abortions before
FFTIP nor did they distinguish first-
trimester from later abortions (Valaoras
et al., 1969; Yuasa & MacMahon, 1970;
Lin et al., 1971; MacMahon et al., 1973).
Our finding makes biological sense if one
considers breast tissue as merely pro-
liferating in early first pregnancy; the
protective effect of first full-term preg-
nancy is then brought about by a com-
bination ofcell differentiation and possibly
permanently altered hormone levels (Pike
et al., 1979; Cole et al., 1976). Ifthis finding
is substantiated and if it continues to be a
strong risk factor into middle age, it will
be of major importance, since abortion
before FFTP has recently become in-
creasingly common in many countries.
We are most grateful to Ms Alice Avila for sec-
retarial assistance during the course ofthe study and
for preparation of the manuscript.
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